Skip to main content

In this file photo taken on July 29, 2013, the headquarters of the British pharmaceutical company GlaxoSmithKline is pictured in west London.

BEN STANSALL/AFP/Getty Images

GlaxoSmithKline plans to split into two businesses – one for prescription drugs and vaccines, the other for over-the-counter products – after forming a new joint venture with Pfizer’s consumer health division.

The revamp is the boldest move yet by GSK Chief Executive Emma Walmsley, who took over last year.

It will lead to the creation of a consumer health giant with a market share of 7.3 per cent, well ahead of its nearest rivals Johnson & Johnson, Bayer and Sanofi, all on around 4 per cent.

Story continues below advertisement

Walmsley has previously played down the idea of breaking up the group, something that a number of investors have called for over the years.

On Wednesday, however, she announced that GSK and Pfizer would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 percent-owned by the British company, in an all-equity transaction.

GSK said the deal laid the foundation for the creation of two new UK-based global companies focused on pharma/vaccines and consumer health care within three years of the transaction closing.

For Pfizer, the deal resolves the issue of what to do with its consumer health division, which includes Advil painkillers and Centrum vitamins, after an abortive attempt to sell it outright earlier this year.

GSK, whose consumer products include Sensodyne toothpaste and Panadol painkillers, had withdrawn from that earlier Pfizer auction process but Walmsley said the opportunity to strike an all-equity deal cleared the way for the new agreement.

“It’s something we’ve been able to do quickly and quietly,” she told reporters in a conference call.

“What this deal is all about is the opportunity to strengthen two businesses – a world-leading consumer health care business and a new GSK that is focused on pharma and vaccines.”

Story continues below advertisement

CRYSTALLIZING VALUE

Shareholders welcomed the news and the shares jumped 7 per cent, with Jefferies analysts saying the future separation could crystallize value.

The new joint venture with Pfizer is expected to generate total annual cost savings of 500 million pounds by 2022 for expected total cash costs of 900 million and non-cash charges of 300 million. GSK plans divestments of some 1 billion pounds.

Walmsley said there would be an inevitable impact on jobs but there was also an opportunity for cost savings in procurement and across the supply chain.

The Pfizer deal is expected to boost adjusted earnings and free cash flow in the first full year after closing, which GSK anticipates will occur in the second half of 2019.

Pfizer, which already has a long-standing HIV medicines joint venture with GSK, said the transaction would be slightly accretive in each of the first three years after it closed.

The consumer tie-up follows a deal by GSK earlier this year to buy Novartis’s stake in their consumer joint venture for $13 billion and comes as Walmsley tries to reshape Britain’s biggest drugmaker, which has seen its shares move sideways for years.

Story continues below advertisement

Earlier this month, she agreed to buy cancer drug specialist Tesaro for $5.1 billion to try to revitalize its pharmaceuticals business, a high-priced acquisition that was poorly received by the market.

GSK has lagged rivals in recent years in producing multibillion-dollar blockbusters and it largely sat out a spate of deal making by rivals under previous CEO Andrew Witty.

Seeking to reassure investors of its financial strength, GSK extended its guarantee on the dividend by stating it expected to pay unchanged dividends of 80 pence per share for 2019.

GSK was advised by Citi, J.P. Morgan Cazenove and Greenhill, while Centerview, Guggenheim and Morgan Stanley acted for Pfizer.

Related topics

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies